Context Denosumab discontinuation is characterized by an increase in bone turnover
overriding pretreatment status, a rapid bone loss in the majority and multiple vertebral …

Bone turnover comprises two processes: the removal of old bone (resorption) and the laying
down of new bone (formation). N-terminal propeptide of type I procollagen (PINP) and C …

Objective The objective is to formulate clinical practice guidelines for the pharmacological
management of osteoporosis in postmenopausal women. Conclusions Evidence from …

Denosumab reduces bone resorption and vertebral and nonvertebral fracture risk.
Denosumab discontinuation increases bone turnover markers 3 months after a scheduled …

Objective The development of these guidelines is sponsored by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology …

Introduction The optimal duration of osteoporosis treatment is controversial. As opposed to
bisphosphonates, denosumab does not incorporate into bone matrix and bone turnover is …

The fully human monoclonal antibody denosumab was approved for treatment of
osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces …

Denosumab is a potent antiresorptive agent that substantially increases bone mineral
density and reduces fracture rates at all skeletal sites for as long as it is administered …

We aimed to study the clinical and imaging characteristics of patients sustaining vertebral
fractures after denosumab discontinuation. For this purpose, we conducted a computerized …

Since the receptor activator of nuclear factor-kappa B ligand (RANKL), its cognate receptor
activator of nuclear factor-kappa B (RANK), and the decoy receptor osteoprotegerin (OPG) …